Hepatocellular
carcinoma (HCC) is inflammation-related cancer and the 4th leading
cause of death globally. Neopterin
is an instant biomarker of the cellular immune response and belongs to the
pteridine class. The levels of neopterin are believed to be very closely
linked with the tumor size in patients with HCC. Various studies have proven that neopterin can modulate the cellular
oxidant-antioxidant balance, thus causing cell toxicity. In this study, we
investigated the cytotoxic effects of neopterin alone and in combination with
two of the known cytotoxic agents of doxorubicin and cisplatin together with
vitamin C, a well-known antioxidant agent. SNU-449, Hep3B, Mahlavu, and
PLC/PRF/5 HCC cell lines were used in this study. Our results showed that
increasing concentrations of neopterin does not have any significant
effects on the cytotoxicity while as expected the three other agents
decrease the viability of all subjected cell lines. SNU-449 is the most
resistant HCC cell line among others. Considering the effectivity of
combinational therapy in cancer patients, the effect of various combinations of
neopterin with doxorubicin, cisplatin and vitamin C on the viability of
the most resistant cell line of SNU-449 has been investigated. We found that
the addition of cisplatin to the combination of neopterin and vitamin C, causes
a greater decrease in cell viability of SNU-449 cells compared to the dual
therapy with neopterin and vitamin C, while the addition of doxorubicin to the
same dual therapy, leads to a decrease in the effectivity of it.
Primary Language | English |
---|---|
Subjects | Pharmacology and Pharmaceutical Sciences |
Journal Section | Research Articles |
Authors | |
Publication Date | December 27, 2019 |
Acceptance Date | December 21, 2019 |
Published in Issue | Year 2019 Cilt 2 (Suppl 1) |